KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Total Debt (2016 - 2025)

Historic Total Debt for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $61.7 billion.

  • Pfizer's Total Debt fell 884.63% to $61.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $61.7 billion, marking a year-over-year decrease of 884.63%. This contributed to the annual value of $64.4 billion for FY2024, which is 1105.6% down from last year.
  • As of Q3 2025, Pfizer's Total Debt stood at $61.7 billion, which was down 884.63% from $61.8 billion recorded in Q2 2025.
  • Pfizer's 5-year Total Debt high stood at $72.4 billion for Q4 2023, and its period low was $35.9 billion during Q2 2023.
  • Moreover, its 5-year median value for Total Debt was $61.7 billion (2025), whereas its average is $52.6 billion.
  • Per our database at Business Quant, Pfizer's Total Debt crashed by 3831.14% in 2021 and then surged by 10127.97% in 2023.
  • Over the past 5 years, Pfizer's Total Debt (Quarter) stood at $38.4 billion in 2021, then fell by 6.48% to $35.9 billion in 2022, then soared by 101.28% to $72.4 billion in 2023, then dropped by 11.06% to $64.4 billion in 2024, then decreased by 4.1% to $61.7 billion in 2025.
  • Its last three reported values are $61.7 billion in Q3 2025, $61.8 billion for Q2 2025, and $62.1 billion during Q1 2025.